Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case–Control Study
Anthony J. Esposito(Brigham and Women's Hospital), Tracy J. Doyle(Brigham and Women's Hospital), Hilary J. Goldberg(Harvard University), Rachel K. Putman(Brigham and Women's Hospital), Laura E. Fredenburgh(Brigham and Women's Hospital), Souheil El‐Chemaly(AVEO Oncology (United States)), Aravind Menon(Pulmonary and Critical Care Associates), Gary M. Hunninghake(Hubei University of Science and Technology), Rebecca M. Baron(Brigham and Women's Hospital), Auyon Ghosh(SUNY Upstate Medical University)
American Journal of Respiratory and Critical Care Medicine
September 8, 2020
Cited by 150
Related Papers
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
|New England Journal of Medicine|2011|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Serum Vitamin D Levels and Markers of Severity of Childhood Asthma in Costa Rica
|American Journal of Respiratory and Critical Care Medicine|2009|635
Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities
|New England Journal of Medicine|2011|615